Jeffrey P. George - 27 Mar 2026 Form 4 Insider Report for LENZ Therapeutics, Inc. (LENZ)

Reporting relationship: Director
Issuer ticker: LENZ
Reported as of: 27 Mar 2026
Net transaction value: +$49,890
SEC form: 4
Accepted by SEC: 30 Mar 2026, 08:47:03 UTC
Prior SEC filing: 13 Jun 2025
Next SEC filing: 08 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Daniel R. Chevallard, as Attorney-in-Fact

Key filing fact

Jeffrey P. George filed Form 4 for LENZ Therapeutics, Inc. (LENZ) on 30 Mar 2026.

Key facts

This page summarizes Jeffrey P. George's Form 4 filing for LENZ Therapeutics, Inc. (LENZ).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 30 Mar 2026, 08:47.

Change

Previous filing in this sequence was filed on 13 Jun 2025.
Current net transaction value: +$49,890.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001796789 Primary reporting owner

George Jeffrey P.

Relationship: Director
Address: C/O LENZ THERAPEUTICS, INC., 201 LOMAS SANTA FE, SUITE 300, SOLANA BEACH
Signature: /s/ Daniel R. Chevallard, as Attorney-in-Fact
Signature date: 30 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LENZ transaction

Common Stock

Purchase

Transaction value: $49,890
Shares: +5,592
Change %
Price: $8.92
Shares after: 5,592
Date: 27 Mar 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents the weighted average share price of an aggregate total of 5,592 shares purchased in the price range of $8.80 to $9.12 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.